Zevra Therapeutics (ZVRA) Assets Average (2015 - 2026)

Zevra Therapeutics has reported Assets Average for 12 years, with the latest figure at $281.7 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 60.56% year-over-year to $281.7 million; the trailing twelve-month figure through Mar 2026 stood at $281.7 million (up 60.56% YoY), and the FY2025 full-year result was $231.4 million, up 32.07% from the prior year.
• Assets Average for Q1 2026 stood at $281.7 million, up from $277.4 million in the prior quarter.
• The five-year high for Assets Average was $281.7 million in Q1 2026, with the low at $111.0 million in Q1 2023.
• Historically, Assets Average has averaged $175.6 million across 5 years, with a median of $161.8 million in 2024.
• Annual changes were most pronounced in 2022 — Assets Average soared 154.04% — and 2023, when it decreased 14.05%.
• Zevra Therapeutics' Assets Average stood at $117.4 million in 2022, then surged by 32.53% to $155.7 million in 2023, then climbed by 18.75% to $184.8 million in 2024, then soared by 50.09% to $277.4 million in 2025, then increased by 1.53% to $281.7 million in 2026.
• The last three Assets Average figures came in at $281.7 million (Q1 2026), $277.4 million (Q4 2025), and $263.2 million (Q3 2025), per Business Quant data.